Pharmaceutical Drug Delivery Market - By Route Of Administration (Oral, Injectable, Self-Injectors, Topical, Pulmonary, Nasal, Transmucosal), By Application (Infectious Diseases, Cancer, Cardiovascular, Diabetes, Autoimmune Disease), Facility Of Use (Hosp

Pharmaceutical Drug Delivery Market - By Route Of Administration (Oral, Injectable, Self-Injectors, Topical, Pulmonary, Nasal, Transmucosal), By Application (Infectious Diseases, Cancer, Cardiovascular, Diabetes, Autoimmune Disease), Facility Of Use (Hospitals, Clinics, Home Care Settings, Diagnostic Centers) - Global Forecast to 2032

Global Pharmaceutical Drug Delivery Market size will garner commendable gains through 2032. Surging incidences of chronic diseases such as diabetes, cardiovascular diseases, and arthritis have resulted in increased mortality rates. As per WHO, cardiovascular diseases account for around 17.9 million deaths every year globally. In this regard, many healthcare organizations and pharmaceutical companies are investing notable amounts to boost the efficacy of the medication and its route of administration, creating a broad scope for industry growth.

The overall pharmaceutical drug delivery market is classified into application, route of administration, facility of use, and region.

With respect to the route of administration, the industry share from the oral drug delivery market size will register recognizable growth through 2032. Rising prevalence of infectious, inflammatory, gastrointestinal diseases, and others has increased the demand for oral administration. Moreover, this route of drug administration is also cost-effective and convenient for the elderly and children.

Based on application, the pharmaceutical drug delivery market from the cancer segment will grow at over 8.5% by 2032. Increasing incidences of cancer have increased investments in introducing new pharmaceutical drug delivery methods. Many pharmaceutical companies and healthcare organizations across the globe are investing substantial amounts into cancer research which will also positively affect segment expansion. To illustrate, in March 2023, Pfizer Inc., an American multinational pharmaceutical company, announced over USD 43 billion in cancer research.

Based on the facility of use, the industry is classified into ambulatory surgical centers and clinics, hospitals, home care settings, diagnostic centers, and other facilities of use. The pharmaceutical drug delivery industry from the home care settings segment will grow at more than 7.5% CAGR from 2023 to 2032. Growing geriatric population base and its susceptibility to chronic diseases will support segment growth. Additionally, the high cost-effectiveness of home care settings favors their adoption.

On the regional front, the Asia Pacific pharmaceutical drug delivery industry share will grow at a substantial CAGR from 2023 to 2032. Growing R&D investments by industry players in product innovations are contributing to regional growth. Moreover, the governments across several regional economies are also investing significant amounts into expanding the healthcare infrastructure, which will further work towards regional expansion. As per Invest India, the healthcare industry in India has the potential to reach USD 188 billion by 2030.